Boston, MANCT07029399Now EnrollingIRB Ready

HR+ Breast Cancer Clinical Trial in Boston, MA

Access cutting-edge hr+ breast cancer treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by NiKang Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access hr+ breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hr+ breast cancer treatment provided free

Apply for This Boston Location

Check if you qualify for this hr+ breast cancer clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This HR+ Breast Cancer Study in Boston

The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET * What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET

Sponsor: NiKang Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Able to provide written informed consent
Advanced unresectable or metastatic solid tumor (Part 1, 2 \& 3 only)
Advanced unresectable or metastatic HR+/HER2- breast cancer (Part 4 \& 5 only)
Refractory to or unable to tolerate existing therapies (Part 1, 2 \& 4 only)
Measurable or evaluable disease (Part 1, 2, \& 4 only).
Measurable disease (Part 3 \& 5 only)
Eighteen years of age or older
ECOG status of 0 or 1
Adequate organ function
Patients with female reproductive organs must be surgically sterile, post- menopausal or willing to use effective contraception per protocol
Patients who are capable of insemination must be willing to use highly effective contraception and to refrain from sperm donation during treatment and for 28 days after the last dose
Able to swallow oral meds
Willing to provide tumor tissue

Exclusion Criteria

Advanced solid tumor that is a candidate for curative treatment
History of another malignancy except for the following: adequately treated local basal cell or squamous carcinoma of the skin, in situ cervical cancer, adequately treated papillary noninvasive bladder cancer, other adequately treated Stage I or Stage II cancers currently in complete remission
Not recovered from the effects of prior anticancer therapy
Clinically significant cardiovascular event, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months
Known active CNS metastases and/or carcinomatous meningitis
Active interstitial lung disease requiring treatment
History of uveitis, retinopathy, or other clinically significant retinal disease
Major surgery within 30 days of administration of first dose
Active uncontrolled infectious disease
Significant liver disease (Child Pugh class B or C)
Should not have received any prior selective investigational inhibitors or degraders (Part 5 only)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07029399) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

HR+ Breast Cancer Treatment Options in Boston, MA

If you're searching for hr+ breast cancer treatment options in Boston, MA, this clinical trial (NCT07029399) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hr+ breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hr+ breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Boston, MA

See all breast cancer clinical trials recruiting in Boston — not just this study.

Browse Breast Cancer Trials in Boston →

Browse More Trials by Condition

Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA